Comparison of 9-month angiographic outcomes of Resolute zotarolimus-eluting and everolimus-eluting stents in a real world setting of coronary intervention in Korea

BMC Cardiovascular Disorders

Dong-Ju Choi²  In-Ho Chae²  Goo-Yeong Cho²  Young-Seok Cho²  Jung-Won Suh²  Chang-Hwan Yoon²  Il-Young Oh²  Jin Joo Park²  Tae-Jin Youn²  Joo Myung Lee¹ 

[1] Division of Cardiovascular, Department of Internal Medicine, College of Medicine, Seoul National University and Cardiovascular Center, Seoul National University Hospital, Seoul, Korea;Division of Cardiology, Department of Internal Medicine, College of Medicine, Seoul National University and Cardiovascular Center, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea

关键词: Everolimus-eluting stent;    Resolute zotarolimus-eluting stent;    Quantitative coronary angiography;    Late loss;    Drug eluting stent;    Percutaneous coronary intervention;   

Others  :  857516
DOI  :  10.1186/1471-2261-13-65

 received in 2013-03-01, accepted in 2013-09-03,  发布年份 2013

【 摘 要 】

Background

Clinical outcomes of new-generation drug-eluting stents (DES), Everolimus-eluting stent (EES) or Resolute zotarolimus-eluting stent (R-ZES), have been reported. However, angiographic follow-up data of new-generation DES are limited, especially in Asians. We investigated the angiographic and clinical outcomes of EES and R-ZES in a real-world setting of Korean patients.

Methods

Angiographic and clinical outcomes of 679 patients (866 lesions) who had been treated with EES or R-ZES from Jun 2008 to May 2010 were evaluated. The primary analysis was to compare in-segment late loss at 9 months and the secondary analyses were to compare the clinical outcomes.

Results

In-segment late loss at 9-month follow-up angiography was 0.23 ± 0.52 mm for EES and 0.29 ± 0.64 mm for R-ZES (p = 0.248). In addition, the rate of binary restenosis did not show between-group differences (5.8% vs. 6.8% for EES and R-ZES, respectively, p = 0.716). During a median follow-up of 33 months, there were no significant differences in Kaplan-Meier estimates of target lesion failure (TLF) (7.5% vs. 7.9% for EES and R-ZES, respectively, p = 0.578) and patient-oriented composite outcomes (POCO including all-cause death, any myocardial infarction, and any revascularization, 22.8% vs. 20.1%, p = 0.888). The adjusted hazard ratios for TLF and POCO were 0.875 (95% CI 0.427 - 1.793; p = 0.715) and 1.029 (95% CI 0.642 - 1.650; p = 0.904), respectively, for EES over R-ZES in the propensity score matched group analysis.

Conclusions

In Korean patients undergoing new-generation DES implantation for coronary artery disease, EES and R-ZES showed similar angiographic outcomes at 9 months and comparable clinical outcomes during 2.8 years of median follow-up.

【 授权许可】

   
2013 Lee et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Serruys PW, Kutryk MJ, Ong AT: Coronary-artery stents. N Engl J Med 2006, 354(5):483-495.
• [2]Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, et al.: Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007, 370(9591):937-948.
• [3]Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, et al.: Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007, 356(10):998-1008.
• [4]Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, Brodie B, Hannan E, Harjai K, Jensen LO, et al.: Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation 2009, 119(25):3198-3206.
• [5]Di Lorenzo E, Sauro R, Varricchio A, Carbone G, Cortese G, Capasso M, Lanzillo T, Manganelli F, Mariello C, Siano F, et al.: Long-Term outcome of drug-eluting stents compared with bare metal stents in ST-segment elevation myocardial infarction: results of the paclitaxel- or sirolimus-eluting stent versus bare metal stent in primary angioplasty (PASEO) randomized trial. Circulation 2009, 120(11):964-972.
• [6]Cook S, Ladich E, Nakazawa G, Eshtehardi P, Neidhart M, Vogel R, Togni M, Wenaweser P, Billinger M, Seiler C, et al.: Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation 2009, 120(5):391-399.
• [7]Mauri L, Hsieh WH, Massaro JM, Ho KK, D’Agostino R, Cutlip DE: Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007, 356(10):1020-1029.
• [8]Finn AV, Kolodgie FD, Harnek J, Guerrero LJ, Acampado E, Tefera K, Skorija K, Weber DK, Gold HK, Virmani R: Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 2005, 112(2):270-278.
• [9]Akin I, Schneider H, Ince H, Kische S, Rehders TC, Chatterjee T, Nienaber CA: Second- and third-generation drug-eluting coronary stents: progress and safety. Herz 2011, 36(3):190-196.
• [10]Serruys PW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE, Kelbaek H, van Boven AJ, Hofma SH, Linke A, et al.: Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010, 363(2):136-146.
• [11]Silber S, Windecker S, Vranckx P, Serruys PW: Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet 2011, 377(9773):1241-1247.
• [12]von Birgelen C, Basalus MW, Tandjung K, van Houwelingen KG, Stoel MG, Louwerenburg JH, Linssen GC, Said SA, Kleijne MA, Sen H, et al.: A randomized controlled trial in second-generation zotarolimus-eluting resolute stents versus everolimus-eluting Xience V stents in real-world patients: the twente trial. J Am Coll Cardiol 2012, 59(15):1350-1361.
• [13]de Boer SP, Lenzen MJ, Oemrawsingh RM, Simsek C, Duckers HJ, van der Giessen WJ, Serruys PW, Boersma E: Evaluating the ’all-comers’ design: a comparison of participants in two ’all-comers’ PCI trials with non-participants. Eur Heart J 2011, 32(17):2161-2167.
• [14]Park KW, Lee JM, Kang SH, Ahn HS, Yang HM, Lee HY, Kang HJ, Koo BK, Cho J, Gwon HC, et al.: Safety and efficacy of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice: patient-related and stent-related outcomes from the multicenter prospective excellent and Resolute-Korea registries. J Am Coll Cardiol 2013, 61(5):536-544.
• [15]Serruys P, Foley D, De Feyter PJ: Quantitative coronary angiography in clinical practice. Dordrecht, the Netherlands: Springer; 1994.
• [16]Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, et al.: Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007, 115(17):2344-2351.
• [17]Stefanini GG, Serruys PW, Silber S, Khattab AA, van Geuns RJ, Richardt G, Buszman PE, Kelbaek H, van Boven AJ, Hofma SH, et al.: The impact of patient and lesion complexity on clinical and angiographic outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial (a randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutaneous coronary intervention). J Am Coll Cardiol 2011, 57(22):2221-2232.
• [18]Gu XS, Rosenbaum PR: Comparison of multivariate matching methods: structures, distances, and algorithms. J Comput Graph Stat 1993, 2(4):405-420.
• [19]Cohen J: Statistical power analysis for the behavioral sciences. Edited by Hillsdale NJ. England: Lawrence Erlbaum Associates, Inc; 1977.
• [20]Pinto DS, Stone GW, Ellis SG, Cox DA, Hermiller J, O’Shaughnessy C, Mann JT, Mehran R, Na Y, Turco M, et al.: Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial. J Am Coll Cardiol 2006, 48(1):32-36.